[1]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer [2]https://www.onclive.com/view/fda-approves-durvalumab-for-limited-stage-small-cell-lung-cancer ...
国际肺癌研究协会(International Association for the Study of Lung Cancer)在2023年世界肺癌大会(World Conference on Lung Cancer)上公布了一项3期AEGEAN试验的结果,港安健康国际医疗介绍,与安慰剂加化疗相比,在围手术期新辅助化疗中加用免疫治疗Durvalumab(Imfinzi)可显著改善可切除非小细胞肺癌(NSCLC)患者的...
基于此,研究者们设计了ADRIATIC试验,旨在评估对于放化疗后未发生疾病进展的有限阶段SCLC患者,使用durvalumab(±tremelimumab)进行辅助治疗的效果。研究结果发表在国际顶尖医学期刊NEJM上,题目为Durvalumab after Chemoradiotherapy in Limited-Stage Sm...
“我认为这让像我这样不建议进行预防性颅脑放射治疗的医生感到安心。这种好处仍然存在,”斯皮格尔补充道。 参考来源:‘ FDA approves durvalumab for limited-stage small cell lung cancer. News release. FDA.
前沿信息、药物最新临床、群聊经典案例、专家大咖点评面面俱到！我们每天100%的认真和努力，为您的抗癌之路保驾护航！欢迎点击订阅。”参考文献 1．FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing 2. http://www.nejm.org/doi/full/10.1056/NEJM oa1709937 ...
参考来源:‘ FDA approves durvalumab for limited-stage small cell lung cancer. News release. FDA. December 4, 2024. Accessed December 4, 2024.’注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。 送TA礼物 1楼2024-12-05 11:31回复 ...
FDA approves neoadjuvant/adjuvant duravlumab for resectable non–small cell lung cancer. FDA. August 15, 2024. Accessed March 3, 2025. A study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable non–small cell lung cancer (AEGEAN). ClinicalTrials.gov. Updated January...
研究结果表明,虽然PD-L1高表达患者的ORR更高,但取得疗效的患者中,无论其PD-L1表达水平,疗效均较持久。抗PD-L1单抗durvalumab用于既往经过多线治疗后的晚期NSCLC患者,有较好的临床疗效,且耐受性好。 参考文献:《Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): ...
Introduction: In non-small cell lung cancer (NSCLC), immunotherapy is one of today's most important and ground-breaking systemic treatments, mainly represented by antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death protein 1 or ligand 1 (PD-1/PD-L1). ...
CI：0.61-0.95；p=0.0161）。Durvalumab组和安慰剂组的中位PFS分别为16.6个月（95% CI：10.2-28.2）和9.2个月（95% CI：7.4-12.9）。最常见的不良反应（≥20％）是肺炎或放射性肺炎和疲劳。参考文献 FDA官网Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer药渡数据库 ...